FDA announces Class I recall of ventilators after 3 patient injuries

The U.S. Food and Drug Administration (FDA) has issued a recall on behalf of ventilator manufacturer Percussionaire after a nickel coating was found on the breathing circuits of one of its products. Nickel can react to various drugs used in conjunction with the mechanical ventilator, causing lung injury, airway spasm, anaphylaxis, and possibly death.

There have been three reported injuries associated with use of the Intrapulmonary Percussive Ventilation (IPV) Phasitron 5 breathing circuit. No one has died. However, because of the serious risks the defect poses to patient health, the recall has been given a Class I designation, reserved for the most serious type. 

What is being recalled?

Certain lots of the Percussionaire Phasitron 5 ventilators are subject to the recall. More specifically, the breathing circuits are being recalled because of the nickel coating. 

Percussionaire Phasitron 5 

Here are the recalled part/lot numbers:

  • P5-10/240329, 240412,240430, 240509, 240516, 240614, 240625 
  • P5-HC-5/240321
  • P5-UC-10/240627

Patients and providers are to cease using the devices immediately. 

Next steps

If there’s an emergency situation and recalled Phasitron 5 ventilators must be used, the FDA and Percussionaire have updated safety instructions that operators should follow:

  • Rinse with sterile water after use and allow the ventilator to air dry.
  • Only use saline as the liquid in the nebulization cup.
  • Stop use if unexpected symptoms occur.
  • Do not use the ventilator to deliver medications.
  • Do not use it for more than 2 weeks.
  • Do not use it on any patient in an inflammatory state. 

The company said all customers have received a notice of the recall with instructions on how to obtain replacements. 

The full recall notice can be found here.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup